Combined cancer immunotherapy of PD-1 antibody and c-di-GMP loaded lipid nanoparticles
| Project/Area Number |
16K15102
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Physical pharmacy
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2016-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 薬物送達学 / がん免疫療法 / 脂質ナノ粒子 / アジュバント / STING / 免疫チェックポイント阻害 / 免疫チェックポイント阻害剤 / がん免疫 |
|---|
| Outline of Final Research Achievements |
The present study demonstrated that the combination therapy of programmed cell death 1 (PD-1) antibody and lipid nanoparticles (LNP) carrying cyclic di-GMP (c-di-GMP), an agonist for the stimulator of interferon genes pathway, was effective against the PD-1 therapy resistant tumor. Moreover, the dose of PD-1 antibody was reduced by combining the lipid nanoparticles. Thus, the c-di-GMP loaded LNP can be potent candidate for the combination therapy with PD-1 antibody.
|
Report
(3 results)
Research Products
(9 results)
